{"id":"kpl-914","_chembl":{"chemblId":"CHEMBL5974036","moleculeType":null,"molecularWeight":"558.78"},"_dailymed":null,"_scrapedAt":"2026-03-28T01:58:17.150Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123958,"model":"claude-sonnet-4-5-20250929"},"description":"KPL-914 is an investigational therapeutic agent being developed by Kiniksa Pharmaceuticals for undisclosed indications. Currently in Phase 2 clinical development, the drug's molecular target, mechanism of action, and therapeutic area have not been publicly disclosed by the company.","indications":{"approved":[{"status":"investigational","condition":null,"patientPopulation":null}]},"trialDetails":[{"nctId":"NCT06660732","phase":"PHASE2","title":"Rilonacept in Subjects With Cardiac Sarcoidosis","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-03-05","conditions":"Cardiac Sarcoidosis","enrollment":60},{"nctId":"NCT03737110","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis","status":"COMPLETED","sponsor":"Kiniksa Pharmaceuticals (UK), Ltd.","startDate":"2019-01-07","conditions":"Recurrent Pericarditis","enrollment":86},{"nctId":"NCT03980522","phase":"PHASE2","title":"A Pilot Study of KPL-914 in Recurrent Pericarditis","status":"COMPLETED","sponsor":"Kiniksa Pharmaceuticals (UK), Ltd.","startDate":"2018-01-24","conditions":"Recurrent Pericarditis","enrollment":26}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["rilonacept"],"phase":"phase_2","status":"active","brandName":"KPL-914","genericName":"KPL-914","companyName":"Kiniksa Pharmaceuticals (UK), Ltd.","companyId":"kiniksa-pharmaceuticals-uk-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":1,"visitCount":0,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"withdrawn","approval_date":"2009-10-23T00:00:00.000Z","mah":"Regeneron UK Limited","brand_name_local":"Rilonacept Regeneron (previously Arcalyst)","application_number":"EMEA/H/C/001047"},{"country_code":"EU","regulator":"EMA","status":"withdrawn","approval_date":null,"mah":"Rilonacept FGK Representative Service GmbH","brand_name_local":"Rilonacept FGK Representative Service GmbH","application_number":"EMEA/H/C/006537"}],"trialStats":{"total":1,"withResults":1},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}